MARKET

ACHFF

ACHFF

Arch Biopartners
OTCMQB
0.347
-0.014
-3.75%
Closed 12:41 06/16 EDT
OPEN
0.360
PREV CLOSE
0.360
HIGH
0.360
LOW
0.347
VOLUME
4.70K
TURNOVER
1.64K
52 WEEK HIGH
1.410
52 WEEK LOW
0.290
MARKET CAP
23.54M
P/E (TTM)
-12.3310
1D
5D
1M
3M
1Y
5Y
1D
Arch Biopartners spotlights Phase II LSALT peptide trial for cardiac surgery-associated acute kidney injury at ADA 2026 sessions
PUBT · 06/04 11:50
Arch Biopartners features in American Diabetes Association Thought Leadership Series at Scientific Sessions
PUBT · 06/04 11:41
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Barchart · 06/04 06:41
Arch Biopartners Q2 FY26 net loss narrows to CAD 521,009
PUBT · 06/02 01:37
Arch Biopartners says Royal Columbian Hospital doses first patient in Phase II AKI trial
PUBT · 05/22 10:50
ARCH BIOPARTNERS ANNOUNCES ROYAL COLUMBIAN HOSPITAL HAS DOSED ITS FIRST PATIENT IN ITS PHASE II CARDIAC SURGERY-ASSOCIATED AKI TRIAL
Reuters · 05/22 10:50
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Barchart · 05/22 05:50
Arch Biopartners grants new director 150,000 stock options at $1.05 per share
PUBT · 04/30 12:30
More
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

Webull offers Arch Biopartners Inc stock information, including OTCMQB: ACHFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHFF stock methods without spending real money on the virtual paper trading platform.